# A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Renal Impairment

> **NCT04859439** · PHASE1 · COMPLETED · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 40 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** DBPR108 tablets

## Key facts

- **NCT ID:** NCT04859439
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-15
- **Primary completion:** 2021-11-30
- **Final completion:** 2021-12-31
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2022-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04859439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04859439, "A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Renal Impairment". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT04859439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*